Nacl 0,9% (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
53 | Sjogren syndrome | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03700138 (ClinicalTrials.gov) | June 24, 2019 | 24/8/2018 | Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies | Prospective, Randomised, Placebo-controlled Study of Polyvalent Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies | Primary Sjögren's Syndrome Painful Sensory Neuropathies | Drug: Privigen® 100mg/ml at the dose of 2g/kg of body weight;Drug: NaCl 0,9% | University Hospital, Strasbourg, France | NULL | Recruiting | 18 Years | 80 Years | All | 24 | Phase 3 | France |